Immuto Scientific is pioneering advancements in target discovery by leveraging its AI-enabled structural surfaceomics platform to identify disease-specific structural changes in cell-surface proteins. The company focuses on developing first-in-class therapeutics with an initial emphasis on oncology, utilizing its proprietary technology to reveal novel, targetable surface protein conformations from patient-derived samples. Immuto's platform integrates high-resolution structural proteomics and advanced analytics to unlock new therapeutic opportunities across various diseases, enhancing the precision and safety of drug development.